ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015.
As the research chemical has been introduced to the market only recently, its properties are not fully understood yet. Based on existing data, AB-CHMINACA is expected to have much stronger affinity for CB1 than for CB2 receptors, which is in line with findings for other indazole cannabinoids. The product is available for delivery as a crystalline solid, stable on room temperature and simple to measure and prepare for objective testing.
Warning
Like all other products available from our store, AB-CHMINACA can be used exclusively by qualified researchers for conducting chemical and physical experiments in a properly equipped lab. Please pay attention that some jurisdictions may have recently placed restrictions on this substance and make sure it’s legal in your area of residence before initiating a transaction. Avoid contact with humans or animals at any cost and seek immediate medical attention if the chemical accidentally contaminates living organisms. Apply standard lab safety procedures when working with AB-CHMINACA.



Reviews
There are no reviews yet.